Weight-Loss drug before heart procedure may boost success in AF patients

NCT ID NCT07275697

First seen Jan 04, 2026 · Last updated May 07, 2026 · Updated 22 times

Summary

This study tests whether taking semaglutide (Wegovy) before a standard heart procedure called catheter ablation can help people with atrial fibrillation (an irregular heartbeat) stay free of heart rhythm problems for longer. The trial will enroll 200 adults who are overweight or obese and scheduled for their first ablation. Half will receive semaglutide plus lifestyle advice before the procedure, while the other half gets standard care. All participants will get a small heart monitor implanted to track their rhythm for a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karolinska University Hospital

    Stockholm, 141 86, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.